ストックスクリーナーアプリを入手
2.49
1.97%
-0.05
Lantern Pharma Inc (LTRN) 最新ニュース
Funds report 834,752 Lantern Pharma (LTRN) shares in ownership update - Stock Titan
Lantern Pharma (LTRN) Launches AI Platform for Cancer Research - GuruFocus
Lantern Pharma launches AI platform for rare cancer research By Investing.com - Investing.com Australia
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Can - PharmiWeb.com
Lantern Pharma launches AI platform for rare cancer research - Investing.com
Lantern Pharma Inc. Launches withZeta.ai, the Worlds First Multi Agentic AU Co Scientist for Rare Cancer Drug Discovery and Development - marketscreener.com
Lantern Pharma outlines $15B–$20B market potential as AI-driven pipeline advances and funding needs intensify - MSN
Lantern Pharma Showcases withZeta.ai Platform for Rare Cancers - TipRanks
Lantern Pharma showcases withZeta.ai platform, outlines commercial architecture and near-term revenue strategy - TradingView — Track All Markets
Lantern Pharma (NASDAQ: LTRN) showcases withZeta.ai rare cancer AI - Stock Titan
LTRN Technical Analysis & Stock Price Forecast - Intellectia AI
Lantern Pharma (NASDAQ: LTRN) insider holds 570,000 shares, 5.1% stake - Stock Titan
Why is Lantern Pharma stock soaring Monday? - MSN
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... By GuruFocus - Investing.com Canada
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Stra - GuruFocus
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Lantern Pharma (LTRN) to Showcase AI Innovation in Rare Cancer R - GuruFocus
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026 - Yahoo Finance
Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows - Foster's Daily Democrat
Fed Meeting: Whats the outlook for Lantern Pharma Incs sectorWeekly Market Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Progress Index
LTRN PE Ratio & Valuation, Is LTRN Overvalued - Intellectia AI
LTRN stock gains 18% pre-market: FDA greenlights first pediatric cancer trial for AI-driven drug - MSN
Lantern Pharma’s Dramatic Slide Reflects Key Strategic Uncertainties - timothysykes.com
Lantern Pharma Reports 2025 Financial Results - National Today
Lantern Pharma Inc. Announces Proposed Public Offering of Common Stock - Issuewire
Lantern Pharma Q4 2025 Earnings Call Transcript - MarketBeat
Lantern Pharma Q4 2025 slides: EPS beats as cash runway tightens - Investing.com Australia
Lantern Pharma Announces Termination of Proposed Public Offering - Issuewire
Lantern Pharma Q4 2025 slides: EPS beats as cash runway tightens By Investing.com - Investing.com South Africa
Lantern Pharma Inc. announces plan for best-efforts public offering of common stock. - bitget.com
Lantern Pharma Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Lantern Pharma Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:LTRN) 2026-03-30 - Seeking Alpha
Lantern Pharma (LTRN) Achieves Key Milestones in Oncology Develo - GuruFocus
Lantern Pharma Reports 2025 Results and Pipeline Progress - TipRanks
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - 01net
Lantern Pharma (LTRN) Dismisses False CEO Resignation Rumor - GuruFocus
Lantern Pharma (NASDAQ: LTRN) outlines AI-driven cancer pipeline and going concern risk - Stock Titan
Lantern Pharma (NASDAQ: LTRN) seeks equity via best‑efforts placement with warrants - Stock Titan
Earnings call transcript: Lantern Pharma Q4 2025 sees EPS improvement, stock jumps By Investing.com - Investing.com South Africa
Earnings call transcript: Lantern Pharma Q4 2025 sees EPS improvement, stock jumps - Investing.com Australia
Lantern Pharma (NASDAQ: LTRN) trims 2025 loss as cash runway shrinks into 2026 - Stock Titan
Q4 2025 Lantern Pharma Inc Earnings Call Transcript - GuruFocus
Lantern Pharma : Fourth Quarter 2025 Financial Results Conference Call - marketscreener.com
Lantern Pharma : Fourth Quarter 2025 Presentation - marketscreener.com
Dallas company secures FDA approval for pediatric cancer drug trial - The Business Journals
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report - marketscreener.com
Lantern Pharma (LTRN) price target increased by 25.00% to 25.50 - MSN
Lantern Pharma Shares Rise; What's The Buzz? - RTTNews
Lantern Pharma Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aug Volume: What are Lantern Pharma Incs recent SEC filings showingQuarterly Performance Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
2.19%
0.43%
大文字化:
|
ボリューム (24 時間):